Experimental Elacestrant Seems Effective for Breast Cancer Resistant to Other Types of Hormonal Therapy

episode

Breastcancer.org Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Sex, Confidence & Connection: The Truth About Male Escorts 59 min · 22 Sep 2026 · Vain-ish

Why You Don't Feel Good Enough | Self-Worth with Dr. Marisa Franco 41 min · 22 Sep 2026 · We're Out of Time

Reacting To People’s Diabolical Revenge Stories 18 min · 22 Sep 2026 · The Joe Santagato Show

5 On It & Tim Jenkins breaks down Bears tape (Hour 3) 39 min · 22 Sep 2026 · Rahimi & Grote Show

Patrick Mannelly talks Bears' loss & Ian Happ talks Cubs' outlook (Hour 2) 44 min · 22 Sep 2026 · Rahimi & Grote Show

'Lanterns' Episode 6 Deep Dive | House of R 1h 41m · 22 Sep 2026 · House of R

Report any issue

Source

Recorded08 Dec 2022

Publisherfeeds.megaphone.fm ↗

Handlerec:11088151

Show notes

Doctors are looking for new treatment options for people diagnosed with metastatic hormone receptor-positive, HER2-negative breast cancer that has grown during treatment with hormonal therapy and a CDK4/6 inhibitor. Dr. Virginia Kaklamani is part of the team investigating elacestrant, an oral medicine, to see if offers more benefits than Faslodex (chemical name: fulvestrant), which is the current standard of care. Listen to the podcast to hear Dr. Kaklamani explain: the type of medicine elacestrant is and how it works why it’s important that elacestrant showed benefits for breast cancers with an ESR1 mutation when we might hear if elacestrant is approved by the U.S. Food and Drug Administration (FDA)

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in